Trial Profile
Phase III trial of docetaxel [BIND-014] in patients with non-small cell lung cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Mar 2015 New trial record